Florian Thalhammer
Overview
Explore the profile of Florian Thalhammer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
605
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soriano A, Paterson D, Thalhammer F, Kluge S, Viale P, Watanabe A, et al.
J Glob Antimicrob Resist
. 2025 Jan;
41:272-279.
PMID: 39864656
Objectives: Antibacterial-resistant gram-negative hospital-acquired infections result in significant morbidity and mortality. In clinical trials, ceftolozane/tazobactam (C/T) has been effective against these infections; however, real-world findings are limited. Methods: SPECTRA was...
2.
Jorda A, Ensle D, Eser H, Glotzl F, Riedl B, Szell M, et al.
Clin Microbiol Infect
. 2024 Nov;
31(3):451-458.
PMID: 39505067
Objectives: The real-world effectiveness of the oral antivirals nirmatrelvir-ritonavir and molnupiravir against the SARS-CoV-2 Omicron variant remains uncertain. We aimed to estimate their effectiveness in non-hospitalized adults with COVID-19. Methods:...
3.
Herdina A, Bozdogan A, Aspermair P, Dostalek J, Klausberger M, Lingg N, et al.
Biosens Bioelectron
. 2024 Sep;
267:116807.
PMID: 39341071
This study presents a graphene field-effect transistor (gFET) biosensor with dual detection capabilities for SARS-CoV-2: one RNA detection assay to confirm viral positivity and the other for nucleocapsid (N-)protein detection...
4.
Grob M, Watzinger C, Willinger B, Thalhammer F, Koller W, Rappelsberger A, et al.
Stud Health Technol Inform
. 2024 Aug;
316:1911-1915.
PMID: 39176865
Leveraging the capabilities of a microbiological clinical analytics tool, this study delves into quantifying the public health impact of antibiotic-resistant bacteria. Focusing on eight predominant antibiotic-resistant bacteria, the study utilizes...
5.
Eckmann C, Sunderkotter C, Becker K, Grabein B, Hagel S, Hanses F, et al.
Curr Opin Infect Dis
. 2023 Dec;
37(2):95-104.
PMID: 38085707
Purpose Of Review: This review comments on the current guidelines for the treatment of wound infections under definition of acute bacterial skin and skin structure infections (ABSSSI). However, wound infections...
6.
Senneville E, Cuervo G, Gregoire M, Hidalgo-Tenorio C, Jehl F, Miro J, et al.
Int J Antimicrob Agents
. 2023 Aug;
62(5):106960.
PMID: 37633424
Background: Dalbavancin is a lipoglycopeptide with a long elimination half-life and is currently licensed for the treatment of acute bacterial skin and skin structure infections in adults. Dalbavancin's potential in...
7.
Kainz J, Gawrylkowicz J, Strassl R, Willinger B, Thalhammer F, Rappelsberger A, et al.
Stud Health Technol Inform
. 2023 Jun;
305:153-154.
PMID: 37386983
Hospital wards need immediate information about multi-resistant pathogens and contagious viruses in their hospitalized patients. An alert service configurable with Arden-Syntax-based alert definitions passing through an ontology service to complement...
8.
Brunner-Ziegler S, Bauerle M, Bruhl P, Kornek G, Parschalk B, Savic R, et al.
J Infect Public Health
. 2023 Feb;
16(4):596-602.
PMID: 36842195
Purpose: Post acute sequelae of SARS-CoV-2 infection are defined by persistence or re-occurrence of symptoms six to 12 weeks after SARS-CoV-2 infections. Methods: Twice vaccinated hospital employees after mild to...
9.
Urban N, Valencak J, Bauer W, Thalhammer F, Handisurya A
J Eur Acad Dermatol Venereol
. 2022 Dec;
37(5):e672-e674.
PMID: 36461771
No abstract available.
10.
Spath T, Brunner-Ziegler S, Stamm T, Thalhammer F, Kundi M, Purkhauser K, et al.
Int J Infect Dis
. 2022 Sep;
124:107-112.
PMID: 36126863
Objectives: Human monkeypox (MPX) cases are escalating worldwide. Smallpox vaccination, which was compulsory in Austria until 1981, was reported to confer 85% cross-protection against MPX. Methods: To assess the impact...